

February 25, 2020



# ProMIS Neurosciences Announces Gross Proceeds of \$1,257,970 Related to the Exercise of Common Stock Warrants

TORONTO and CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to report that a total of 6,289,851 of the common share purchase warrants issued on February 10 and February 21, 2017 in a non-brokered private placement were exercised at a price of \$0.20 per share for gross proceeds of \$1,257,970, the vast majority of such proceeds having been received in the last month prior to the February 21, 2020 expiry date.

Commenting on today's announcement, ProMIS Executive Chairman, Eugene Williams, stated: "We are very pleased to receive the proceeds from warrant exercise. The additional funds will now extend our cash life further into 2020. ProMIS remains focused on developing PMN310 as potential best in class therapy for Alzheimer's disease."

## About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at [www.promisneurosciences.com](http://www.promisneurosciences.com) or follow us on [Twitter](#) and [LinkedIn](#).

For media inquiries, please contact:

Shanti Skiffington

[shanti.skiffington@gmail.com](mailto:shanti.skiffington@gmail.com)

Tel. 617 921-0808

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopoulos, President

[nick@alpineequityadv.com](mailto:nick@alpineequityadv.com)

Tel. 617 901-0785

*The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*



Source: ProMIS Neurosciences Inc.